摘要
雷诺嗪是哌嗪类衍生物,多个临床试验证实其有确切的抗心绞痛作用和良好的耐受性及安全性,而对血流动力学无影响,2006年已被批准与其它抗心绞痛药物联合治疗慢性心绞痛,其作用机制可能与部分抑制脂肪酸氧化、抑制晚钠电流从而减轻细胞内钙超载有关。现综述了雷诺嗪的药代动力学特征、可能的作用机制及治疗心绞痛的相关临床试验。
Ranolazine, a piprazine derivative, was approved to manage chronic angina in combination with other drugs for anti-angina in 2006. According to the findings of several clinical trials, ranolazine showed its efficacy and satety and good anti-angina tolerance, and had no obviously adverse effect on hemodynamics. Tile anti-anginal mechanism of ranolazine may be involved with its part inhibition of the β-oxidation of free fatty acid, and the inhibition of late sodium current followed by reduced intracellular calcium overload. This article reviews research involving ranolazine, focusing on its pharmaeokinetics, potential mechanism of anti-angina, and clinical trials.
出处
《心血管病学进展》
CAS
2007年第6期970-975,共6页
Advances in Cardiovascular Diseases
